JP2014510080A5 - - Google Patents

Download PDF

Info

Publication number
JP2014510080A5
JP2014510080A5 JP2013557924A JP2013557924A JP2014510080A5 JP 2014510080 A5 JP2014510080 A5 JP 2014510080A5 JP 2013557924 A JP2013557924 A JP 2013557924A JP 2013557924 A JP2013557924 A JP 2013557924A JP 2014510080 A5 JP2014510080 A5 JP 2014510080A5
Authority
JP
Japan
Prior art keywords
amino
edc
group
linker
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013557924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510080A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/028585 external-priority patent/WO2012122514A1/en
Publication of JP2014510080A publication Critical patent/JP2014510080A/ja
Publication of JP2014510080A5 publication Critical patent/JP2014510080A5/ja
Pending legal-status Critical Current

Links

JP2013557924A 2011-03-09 2012-03-09 細胞外標的化薬物複合体 Pending JP2014510080A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161450795P 2011-03-09 2011-03-09
US61/450,795 2011-03-09
US201161500756P 2011-06-24 2011-06-24
US61/500,756 2011-06-24
US201161507882P 2011-07-14 2011-07-14
US61/507,882 2011-07-14
US201161551287P 2011-10-25 2011-10-25
US61/551,287 2011-10-25
PCT/US2012/028585 WO2012122514A1 (en) 2011-03-09 2012-03-09 Extracellular targeted drug conjugates

Publications (2)

Publication Number Publication Date
JP2014510080A JP2014510080A (ja) 2014-04-24
JP2014510080A5 true JP2014510080A5 (enExample) 2015-06-25

Family

ID=46798582

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013557924A Pending JP2014510080A (ja) 2011-03-09 2012-03-09 細胞外標的化薬物複合体

Country Status (4)

Country Link
US (1) US20140079722A1 (enExample)
EP (1) EP2683737A4 (enExample)
JP (1) JP2014510080A (enExample)
WO (1) WO2012122514A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2754397T3 (es) * 2013-10-11 2020-04-17 Asana Biosciences Llc Conjugados de proteína-polímero-fármaco
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
RU2017112748A (ru) 2014-11-17 2018-12-19 Арно Терапьютикс, Инк. Композиции онапристона пролонгированного действия и способы
US20190008983A1 (en) 2015-07-31 2019-01-10 James R. Prudent Extracellular drug conjugates targeting cd20
CA2998924A1 (en) 2015-09-25 2017-03-30 Context Biopharma Inc. Methods of making onapristone intermediates
CA3008422A1 (en) 2015-12-15 2017-06-22 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EA201892260A1 (ru) 2016-04-07 2019-03-29 Дзе Джонс Хопкинс Юниверсити Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
EP1789090A2 (en) * 2004-09-02 2007-05-30 Bionaut Pharmaceuticals, Inc. Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors
SV2007002227A (es) * 2004-09-10 2007-03-20 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
WO2006137354A1 (ja) * 2005-06-21 2006-12-28 Medical & Biological Laboratories Co., Ltd. アミロイド線維形成に対する阻害活性を有する抗体
WO2008121797A1 (en) * 2007-03-28 2008-10-09 Novartis Ag Fxdy5 modulators for treating, diagnosing, and detecting cancer
SG189817A1 (en) * 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
US8361973B2 (en) * 2008-08-07 2013-01-29 Centrose, Llc Glycoside compounds and pharmaceutical compositions thereof
RU2011111640A (ru) * 2008-08-29 2012-10-10 Симфоген А/С (Dk) Антитела против cd5
JP2013504585A (ja) * 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体

Similar Documents

Publication Publication Date Title
JP2014510080A5 (enExample)
JP2015534577A5 (enExample)
HRP20220399T1 (hr) Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost
JP2016520082A5 (enExample)
JP2019501204A5 (enExample)
JP2015534578A5 (enExample)
JP2023534292A5 (enExample)
JP2022058802A5 (enExample)
JP2011046732A5 (enExample)
JP2018536632A5 (ja) Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子
ME02377B (me) Anti-igf antitijela
JP2009501800A5 (enExample)
JP2016502504A5 (enExample)
JP2012067116A5 (enExample)
JP6425653B2 (ja) 抗腫瘍剤及び抗腫瘍効果増強剤
WO2014142220A1 (ja) 抗腫瘍剤
WO2016204193A1 (ja) 抗がん剤
JP2019524713A5 (enExample)
CN101856352A (zh) 青蒿素及其衍生物对化疗剂的协同作用
JP2015517529A5 (enExample)
CN112292128A (zh) Ep4抑制剂和其用途
JP2023542093A (ja) 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用
WO2019072220A1 (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
JP2020518610A5 (enExample)
JP2017052789A (ja) Ｖｅｇｆ阻害剤とイリノテカンとを含有する抗腫瘍性の組み合わせ